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ETATE-OF-THE-ART PAPER1283HDL and Coronary Heart Diseaseradeep Natarajan, Kausik K. Ray, Christopher P. Cannon
opulation studies have consistently demonstrated an inverse association between high-density
ipoprotein (HDL) cholesterol and the risk of coronary heart disease. In this review,
atarajan and colleagues explore the potential protective mechanisms of HDL and how
urrent and future therapies can exploit these beneficial properties. The clinical evidence
upporting various interventions to raise HDL, from increased alcohol consumption to niacin,
re reviewed. Several newer agents are discussed including agents that target cholesterol ester
ransfer protein and several designed to modify apolipoprotein A1 activity. The results of
everal large clinical outcomes trials currently underway are necessary to define the clinical role
f currently available and emerging therapies to raise HDL.EART FAILURE1300Clopidogrel May Improve Post-MI Outcomes for Those With Heart Failureisbeth Bonde, Rikke Sorensen, Emil Loldrup Fosbøl, Steen Zabell Abildstrøm, Peter Riis Hansen, Lars Kober,
ina Ken Schramm, Ditte-Marie Bretler, Peter Weeke, Jonas Olesen, Christian Torp-Pedersen,
unnar Hilmar Gislason
onde and colleagues studied the post-myocardial infarction (MI) patients with heart failure
HF) who did not undergo percutaneous coronary intervention (PCI) and the potential
enefits of clopidogrel using administrative records from the Danish health system. Over
0,000 patients with first MI and not undergoing PCI within 30 days from discharge were
dentified. Patients were identified as having HF based on either a discharge diagnosis of HF
r a prescription for loop diuretics. The risk of death was significantly lower in those who
eceived clopidogrel (hazard ratio: 0.86). No difference was observed among patients without
F (hazard ratio: 0.98). Clopidogrel use is associated with reduced mortality in patients with
first MI and HF that do not undergo PCI.
ditorial Comment: Victor L. Serebruany, p. 1308(continued on page A-21)
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EARDIOVASCULAR RISK1310Pre-Diabetes and the Risk for Cardiovascular Disease: A Systematic Reviewarl S. Ford, Guixiang Zhao, Chaoyang Li
his study by Ford and colleagues sought to estimate the additive risk for cardiovascular
isease associated with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT).
n 18 publications with information about IFG (110 to 125 mg/dl), the summary estimate of
elative risk was 1.20 compared to those with normoglycemia. In 8 publications that
xamined IGT, the summary estimate of relative risk was also 1.20. IFG and IGT are
ssociated with modest increases in the risk for cardiovascular disease.ARDIOVASCULAR RISK1318Meta-Analysis Confirms Utility of Aortic Pulse Wave Velocity for Predicting Eventsharalambos Vlachopoulos, Konstantinos Aznaouridis, Christodoulos Stefanadis
lachopoulos and colleagues meta-analyzed 15 longitudinal studies which evaluated aortic
ulse wave velocity (PWV) and followed 12,373 subjects for a mean follow-up of 7.3 years.
he pooled relative risk (RR) of clinical events increased in a stepwise, linear-like fashion
rom the first to the third tertile of aortic PWV. The pooled RR of total cardiovascular
vents, cardiovascular mortality, and all-cause mortality were 2.23, 2.19, and 2.08, respectively.
n increase of aortic PWV by 1 m/s corresponded to a risk factor-adjusted risk increase of
11% for all 3 outcomes. This analysis confirms that aortic stiffness measured by aortic PWVs a strong predictor of future cardiovascular events and all-cause mortality.ARDIOVASCULAR RISK
1328ationally Representative Sample Links Light
Alcohol Assumption to Improved Cardiovascular Outcomesenneth J. Mukamal, Chiung M. Chen, Sowmya R. Rao, Rosalind A. Breslow
ukamal and colleagues studied the relationship between alcohol consumption and
ardiovascular risk using the National Health Interview Survey. This annual survey of a
ationally representative sample of U.S. adults includes questions about alcohol consumption.
ortality was ascertained through linkage to the National Death Index. Light and moderate
olumes of alcohol consumption were inversely associated with cardiovascular mortality with
elative risks of 0.69 and 0.62 compared to lifetime abstainers. This large, nationally
epresentative sample of U.S. adults, shows a consistent reduction in cardiovascular risk
mong light and moderate alcohol consumers.
ditorial Comment: Arthur L. Klatsky, p. 1336(continued on page A-24)
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sARDIOVASCULAR RISK1339Meta-Analysis Confirms Benefits of Light-to-Moderate Alcohol Consumptionimona Costanzo, Augusto Di Castelnuovo, Maria Benedetta Donati, Licia Iacoviello, Giovanni de Gaetano
here is conflicting guidance on the benefits of alcohol consumption for patients with known
ardiovascular disease. Costanzo and colleagues performed a meta-analysis of 8 studies that
xamined the relationship between alcohol and included over 16,000 patients with a history of
ardiovascular disease. The results showed a J-shaped curve for cardiovascular mortality with
aximal protection at 26 g/day of alcohol. Similar results were found on total mortality, but
he maximal protection was in the range of 5 to 10 g/day. Light-to-moderate alcohol
onsumption is associated with improved outcomes in patients with known cardiovascular
isease.HRONIC CORONARY ARTERY DISEASE1348Results of Intensive Multifactorial Risk Factor Reduction in the COURAGE Trialavid J. Maron, William E. Boden, Robert A. O’Rourke, Pamela M. Hartigan, Karen J. Calfas,
. B. John Mancini, John A. Spertus, Marcin Dada, William J. Kostuk, Merril Knudtson, Crystal L. Harris,
teven P. Sedlis, Robert G. Zoble, Lawrence M. Title, Gilbert Gosselin, Shah Nawaz, Gerald T. Gau,
lvin S. Blaustein, Eric R. Bates, Leslee J. Shaw, Daniel S. Berman, Bernard R. Chaitman,
illiam S. Weintraub, Koon K. Teo, for the COURAGE Trial Research Group
his paper describes the multiple lifestyle and pharmacologic interventions, and their
ffectiveness, used in the COURAGE (Clinical Outcomes Utilizing Revascularization and
ggressive Drug Evaluation) trial of patients with stable coronary disease. All patients,
egardless of assignment to either percutaneous coronary intervention or optimal medical
herapy, received equivalent lifestyle and pharmacologic interventions for secondary
revention. Therapy was administered by nurse case managers according to protocols. There
ere significant reductions in the proportion of smokers, in the consumption of saturated fat,
n systolic blood pressure, and in low-density lipoprotein cholesterol with the results
aintained for 5 years. Nurse case managers using treatment protocols can achieve significant
mprovements in cardiovascular risk factors.ditorial Comment: Patrick T. O’Gara, p. 1359HRONIC CORONARY ARTERY DISEASE1362Statins May Reduce Post-MI Mortality by 35% in Patients >80 Years of Agelas Gränsbo, Olle Melander, Lars Wallentin, Johan Lindbäck, Ulf Stenestrand, Jörg Carlsson, Jan Nilsson
ränsbo and colleagues used a large Swedish registry to study if statin treatment is effective
nd safe in very elderly (80 years of age) myocardial infarction (MI) patients. Over 20,000
atients with an age 80 years who were admitted with the diagnosis of acute MI were
ollowed for mortality. All-cause mortality was significantly lower in patients with statin
reatment at discharge with relative risk ranging from 0.55 to 0.66. There was no evidence of
n increase in cancer mortality in statin-treated patients. These results suggest that statins
afely reduce cardiovascular mortality in very elderly post-MI patients.(continued on page A-25)
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oEART RHYTHM DISORDERS1370Post-Operative Atrial Fibrillation Linked to Worse Long-Term Mortalityikhael F. El-Chami, Patrick Kilgo, Vinod Thourani, Omar M. Lattouf, David B. Delurgio,
obert A. Guyton, Angel R. Leon, John D. Puskas
l-Chami and colleagues investigated the association between new-onset atrial fibrillation
fter coronary artery bypass grafting (CABG) (post-operative atrial fibrillation [POAF]) and
ong-term mortality in over 16,000 who underwent isolated CABG. New-onset atrial
brillation occurred in 18.5% of patients. POAF independently predicted long-term mortality
hazard ratio: 1.21) during a mean follow-up of 6 years. This risk was diminished when
atients were discharged on warfarin. POAF independently predicts long-term mortality but
nticoagulation may ameliorate this risk.PEDIATRIC CARDIOLOGY EDIATRIC CARDIOLOGY1377Limited Efficacy of Medical Therapy for Pediatric Dilated Cardiomyopathyaul F. Kantor, Jonathan R. Abraham, Anne I. Dipchand, Lee N. Benson, Andrew N. Redington
ngiotensin-converting enzyme inhibitors (ACEIs) and beta-adrenergic receptor blockers
BBs) improve survival in adults with dilated cardiomyopathy (DC), but their effectiveness in
hildren has not been confirmed. Kantor and colleagues performed a single institution
etrospective review of all diagnosed cases of DC and related phenotypic variants between
976 and 2005. The 5-year transplant-free survival rate was 56%, and did not differ in those
reated solely with digoxin, an ACEI but no BB, or both an ACEI and BB. DC in
hildhood has a high risk of death or requirement for transplantation, despite medical therapy
hich has significantly improved outcomes in adults.CELL THERAPY ELL THERAPY
1385BC Contamination Impairs the Efficacy of
Autologous Mononuclear Cell Therapy for Post-MI PatientsR
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b) irgit Assmus, Torsten Tonn, Florian H. Seeger, Chang-Hwan Yoon, David Leistner, Jens Klotsche,
olker Schächinger, Erhard Seifried, Andreas M. Zeiher, Stefanie Dimmeler
ost of the clinical trials testing bone marrow-derived progenitor cells (BMCs) to augment
ecovery after an acute myocardial infarction have used autologously derived samples. This
equires isolation of cells from each patient and, thus, the cell composition and function may
ary. Assmus and colleagues studied samples collected from the REPAIR-AMI (Reinfusion
f Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial
nd found that contamination of the final cell product with red blood cells (RBCs) is an
ndependent predictor of reduced functional recovery. This retrospective statistical analysis was
urther prospectively validated and confirmed by experimental studies showing that ex vivo
ncubation of BMC with RBC dose-dependently reduced the viability and functional activity
f the BMC in vitro.
